Framingham, MA, September 27, 2012 – Dilon Devices announced today that the MarginProbe System will be used at the Agaplesion Markus Hospital, in Frankfurt, Germany. The Agaplesion Markus Hospital is the largest breast center in the Frankfurt area, treating over 400 primary breast cancer cases annually.
“In my previous work with the MarginProbe System, we saw a significant reduction in the number of patients who had to come back for additional surgeries due to positive margins” said Priv.-Doz. Dr. med. Marc Thill, Head of the Department of Gynecology and Obstetrics and the Breast Cancer Center at Agaplesion Markus Hospital, Frankfurt. “We are thrilled to make this innovation available to patients here in Frankfurt. I believe that this technology represents a real breakthrough for breast conserving surgery.
“Our collaboration with Dr. Thill and the Agaplesion Markus Hospital is a terrific boost for patients in Frankfurt,” says Dune’s Chief Executive Officer Dan Levangie. “By reducing the chances of going back for multiple surgeries, the MarginProbe system can significantly improve patients’ experiences being treated for breast cancer. We are excited to continue to work with Dr. Thill at Agaplesion Markus Hospital.”
About Dilon Devices
Dilon Devices was founded in 2002 by Dr. Dan Hashimshony to realize the extraordinary medical potential of its proprietary tissue characterization technology. Offering surgeons and radiologists the real time ability to identify cancerous tissues and react immediately, this technology holds the promise for a broad range of surgical and diagnostic applications. The MarginProbe System is Dune’s first commercial product and is commercially available in Europe. The MarginProbe device is an investigational device that is not yet available for sale in the U.S.
Dilon Devices is a privately held company financed by Apax Partners since 2004. It has offices in the U.S., Israel, and Switzerland. For more information, please visit www.dilon.com
Director of Marketing